食管癌:流行病学、风险因素、诊断与治疗
食管癌预后差、死亡率高,2016年美国估计新发16,910例、死亡15,910例。鳞状细胞癌和腺癌占95%以上,前者多见于非工业化国家,风险因素包括吸烟、饮酒和贲门失弛缓症;后者是发达国家主要类型,风险因素包括慢性胃食管反流病、肥胖和吸烟。吞咽困难伴或不伴非意愿性体重下降是最常见首发症状,早期常无症状。确诊后应行PET-CT初始分期,无远处转移者行超声内镜确定肿瘤深度和淋巴结受累。局部肿瘤可行内镜下黏膜切除,区域肿瘤行食管切除术、新辅助化疗、放化疗或联合治疗,不可切除或远处转移者行姑息治疗。尚无特异性预防策略,也无食管癌筛查推荐。
要点
- 吞咽困难伴或不伴非意愿性体重下降是食管癌最常见首发症状,早期常无症状。
- 有症状即应低阈值行内镜检查以评估食管癌。
- 确诊后PET-CT用于初始分期,无远处转移者行超声内镜评估肿瘤深度和淋巴结。
核心结论
- 食管癌预后差、死亡率高,鳞状细胞癌和腺癌占95%以上,诊断和治疗需根据分期选择不同策略。
研究设计与样本
- 本文为综述,汇总食管癌的流行病学、风险因素、临床表现、诊断分期、治疗和预防筛查相关内容。
主要发现
- 2016年美国估计食管癌新发16,910例、死亡15,910例。
- 鳞状细胞癌重要风险因素包括吸烟、饮酒和贲门失弛缓症;腺癌重要风险因素包括慢性胃食管反流病、肥胖和吸烟。
- 吞咽困难伴或不伴非意愿性体重下降是最常见首发症状,早期常无症状。
- 确诊后PET-CT用于初始分期,无远处转移者行超声内镜确定肿瘤深度和淋巴结受累。
- 局部肿瘤可行内镜下黏膜切除,区域肿瘤行食管切除术、新辅助化疗、放化疗或联合治疗,不可切除或远处转移者行姑息治疗。
关键数值与推荐
- 鳞状细胞癌和腺癌占食管癌95%以上。
- 有症状即应低阈值行内镜检查。
- 确诊后行PET-CT初始分期,无远处转移者行超声内镜分期。
- 尚无特异性预防策略,也无食管癌筛查推荐。
临床怎么用
- 对吞咽困难或非意愿性体重下降患者应低阈值行内镜评估。
- 确诊后按分期选择PET-CT和超声内镜进行分期。
- 根据分期选择内镜下黏膜切除、手术、新辅助化疗、放化疗或姑息治疗。
局限性
- 本文为综述,未报告原始研究数据或系统评价方法。
- 2016年流行病学数据可能已过时。
- 未涉及特异性预防策略和筛查推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Esophageal cancer has a poor prognosis and high mortality rate, with an estimated 16,910 new cases and 15,910 deaths projected in 2016 in the United States. Squamous cell carcinoma and adenocarcinoma account for more than 95% of esophageal cancers. Squamous cell carcinoma is more common in nonindustrialized countries, and important risk factors include smoking, alcohol use, and achalasia. Adenocarcinoma is the predominant esophageal cancer in developed nations, and important risk factors include chronic gastroesophageal reflux disease, obesity, and smoking. Dysphagia alone or with unintentional weight loss is the most common presenting symptom, although esophageal cancer is often asymptomatic in early stages. Physicians should have a low threshold for evaluation with endoscopy if any symptoms are present. If cancer is confirmed, integrated positron emission tomography and computed tomography should be used for initial staging. If no distant metastases are found, endoscopic ultrasonography should be performed to determine tumor depth and evaluate for nodal involvement. Localized tumors can be treated with endoscopic mucosal resection, whereas regional tumors are treated with esophagectomy, neoadjuvant chemotherapy, chemoradiotherapy, or a combination of modalities. Nonresectable tumors or tumors with distant metastases are treated with palliative interventions. Specific prevention strategies have not been proven, and there are no recommendations for esophageal cancer screening.
引用
- Short MW, Burgers KG, Fry VT, et al. Esophageal Cancer. Am Fam Physician. 2017. PMID: 28075104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。